S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Critical asset just had biggest fall on record (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Critical asset just had biggest fall on record (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Critical asset just had biggest fall on record (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Critical asset just had biggest fall on record (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift

Delta 9 Cannabis (DN) Competitors

C$0.02
0.00 (0.00%)
(As of 02/21/2024 ET)

DN vs. CTX, VPH, WLLW, TMD, and AEZS

Should you be buying Delta 9 Cannabis stock or one of its competitors? The main competitors of Delta 9 Cannabis include Crescita Therapeutics (CTX), Valeo Pharma (VPH), Willow Biosciences (WLLW), Titan Medical (TMD), and Aeterna Zentaris (AEZS). These companies are all part of the "medical" sector.

Delta 9 Cannabis vs.

Delta 9 Cannabis (TSE:DN) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Delta 9 Cannabis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Crescita Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Crescita Therapeutics received 51 more outperform votes than Delta 9 Cannabis when rated by MarketBeat users. However, 100.00% of users gave Delta 9 Cannabis an outperform vote while only 67.42% of users gave Crescita Therapeutics an outperform vote.

CompanyUnderperformOutperform
Delta 9 CannabisOutperform Votes
9
100.00%
Underperform Votes
No Votes
Crescita TherapeuticsOutperform Votes
60
67.42%
Underperform Votes
29
32.58%

Crescita Therapeutics has lower revenue, but higher earnings than Delta 9 Cannabis. Crescita Therapeutics is trading at a lower price-to-earnings ratio than Delta 9 Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delta 9 CannabisC$71.15M0.07-C$22.10M-C$0.15-0.17
Crescita TherapeuticsC$18.83M0.48C$1.06M-C$0.03-15.00

In the previous week, Crescita Therapeutics had 1 more articles in the media than Delta 9 Cannabis. MarketBeat recorded 1 mentions for Crescita Therapeutics and 0 mentions for Delta 9 Cannabis. Delta 9 Cannabis' average media sentiment score of 0.00 equaled Crescita Therapeutics'average media sentiment score.

Company Overall Sentiment
Delta 9 Cannabis Neutral
Crescita Therapeutics Neutral

Delta 9 Cannabis has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Crescita Therapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500.

Crescita Therapeutics has a net margin of -3.49% compared to Delta 9 Cannabis' net margin of -31.06%. Crescita Therapeutics' return on equity of -3.37% beat Delta 9 Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Delta 9 Cannabis-31.06% -256.71% -11.78%
Crescita Therapeutics -3.49%-3.37%-2.99%

Summary

Crescita Therapeutics beats Delta 9 Cannabis on 9 of the 12 factors compared between the two stocks.


Get Delta 9 Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for DN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DN vs. The Competition

MetricDelta 9 CannabisDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$5.21MC$1.15BC$4.97BC$5.06B
Dividend YieldN/A2.97%2.91%5.63%
P/E Ratio-0.17128.7995.3025.48
Price / Sales0.0710,891.593,262.611,283.47
Price / Cash4.4710.0089.1479.61
Price / Book-2.503.494.282.57
Net Income-C$22.10MC$59.26MC$112.46MC$297.06M
7 Day PerformanceN/A6.67%0.71%0.98%
1 Month PerformanceN/A7.71%5.96%2.21%
1 Year PerformanceN/A8.39%7.25%2.70%

Delta 9 Cannabis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTX
Crescita Therapeutics
0 of 5 stars
C$0.48
flat
N/A-39.2%C$9.60MC$18.83M-16.0062
VPH
Valeo Pharma
0 of 5 stars
C$0.15
-11.8%
N/AN/AC$14.80MC$53.91M-0.47110
WLLW
Willow Biosciences
0 of 5 stars
C$0.13
flat
N/A+8.7%C$16.15MC$1.59M-1.0032News Coverage
Gap Up
TMD
Titan Medical
0 of 5 stars
C$0.09
-19.0%
N/A-71.4%C$9.59MC$17.13M-0.2033Gap Down
AEZS
Aeterna Zentaris
0 of 5 stars
C$2.41
+0.4%
N/A-48.5%C$11.71MC$6.86M-0.3711News Coverage

Related Companies and Tools

This page (TSE:DN) was last updated on 2/22/2024 by MarketBeat.com Staff